BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

By WebmasterSeptember 20, 2022November 1st, 2024No Comments

Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

See more here

Previous PostVenatorx Pharmaceuticals Awarded BARDA Project BioShield Contract
Next PostRocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostVenatorx Pharmaceuticals Awarded BARDA Project BioShield Contract

Next PostRocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy